Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE
Pharma Mar S.A.
Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome
1 trial -
Azacitidine
Takeda Pharmaceuticals International AG
Myelodysplastic Syndrome
1 trial -
Azacitidine, Cedazuridine, Azacitidine, Vidaza 25 mg/ml powder for suspension for injection, Azacitidine, Cedazuridine
Taiho Pharma Netherlands B.V.
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
Azelastine hydrochloride and Fluticasone propionate
Teva Pharma GmbH
Seasonal Allergic Rhinitis
1 trial -
Azetukalner
Xenon Pharmaceuticals
Major Depressive Disorder
3 trials -
Azetukalner
Xenon Pharmaceuticals
Bipolar Depression
1 trial -
Azetukalner
Xenon Pharmaceuticals
Bipolar Disorder
1 trial -
Azilsartan
Takeda Pharmaceuticals International AG
Pediatric Hypertension
2 trials -
Azilsartan Medoxomil
Takeda Pharmaceuticals International AG
Hypertension
7 trials -
Azilsartan Medoxomil and amlodipine
Takeda Pharmaceuticals International AG
Hypertension
1 trial -
Azilsartan medoxomil and chlorthalidone
Takeda Pharmaceuticals International AG
Safety
1 trial -
Azilsartan medoxomil and chlorthalidone
Takeda Pharmaceuticals International AG
Essential Hypertension
4 trials -
Azilsartan medoxomil and chlorthalidone
Takeda Pharmaceuticals International AG
Hypertension
2 trials -
Azilsartan medoxomil and olmesartan
Takeda Pharmaceuticals International AG
Hypertension
1 trial -
Azilsartan medoxomil with or without add-on chlorthalidone
Takeda Pharmaceuticals International AG
Hypertension
1 trial -
Azilsartan medoxomil/placebo
Takeda Pharmaceuticals International AG
Essential Hypertension
1 trial -
BAX 326
Takeda Pharmaceuticals International AG
Hemophilia B
1 trial -
BAX 326 (Recombinant factor IX)
Takeda Pharmaceuticals International AG
Hemophilia B
1 trial -
BAX326
Takeda Pharmaceuticals International AG
Hemophilia B
1 trial -
BAX855
Takeda Pharmaceuticals International AG
Hemophilia A
1 trial -
BAY 1841788, TRIPTORELIN
Cancer Prevention Pharma (Ireland) Limited
Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).
1 trial -
BDP
Teva Pharma GmbH
Allergic Rhinitis
1 trial -
BDP HFA
Teva Pharma GmbH
Seasonal Allergic Rhinitis
1 trial -
BDP Nasal Aerosol
Teva Pharma GmbH
Allergic Rhinitis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources